Compare Merck & Co., Inc. (MRK) vs Open Text Corporation (OTEX) Price & Performance

Merck & Co., Inc.Trade

Open Text CorporationTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Open Text Corporation — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Open Text Corporation trades at $22.77 (market cap $5.61B). The key difference: Merck & Co., Inc. is far larger — about 54.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.72%). Which is the better fit depends on your goals.

	MRK	OTEX
Market Cap	$307.25B	$5.61B
Sector	Health	Technology
52-Week High	$129.52	$39.69
52-Week Low	$77.60	$20.01
Enterprise Value	$350.66B	$10.77B
Dividend Yield	2.73%	4.72%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Open Text Corporation

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

OTEX

Open Text offers 4.7% dividend and buybacks, trading at 11x earnings amid mixed growth and AI risks.Seeking Alpha · 4 days agoBullish OpenText appoints Jill Larsen to board, replacing Kristen Ludgate who resigns for personal reasons.PRNewsWire · 4 days agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Open Text Corporation

Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.